XORTX Therapeutics Inc. announced the presentation of new research findings at the American Society of Nephrology meeting being held November 3, 2023 in Philadelphia. The abstract entitled "The Effect of Lowering Uric Acid with a Xanthine Oxidase Inhibitor on PKD in Mice" was reviewed by the ASN review panel for scientific merit and novel discoveries. The studies were conducted at the University of Colorado in the independent laboratory of Dr. Charles Edelstein and were sponsored by XORTX.

Upon analysis, results of the studies support the conclusion that moderate soluble, but not saturating, circulating uric acid can: accelerate kidney expansion rate and worsen kidney function; be a mechanism of kidney injury in Autosomal Dominant Polycystic Kidney Disease ("ADPKD") even in the absence of uric acid crystal formation; and be associated with increased pro-inflammation cytokines. The results notably also support the finding that a threshold of xanthine oxidase inhibition /uricemia.